Citations

Clear

4 citation(s) found for "Nguyen, Adam".

Shared ligand-blocking mechanism but distinct conformational modulation by α5-targeting antibodies BIIG2 and MINT1526A
Nguyen, Adam , Cordara, Gabriele , Chan, Matthew C. , Johannesen, Hedda , Charlesworth, M. Cristine , Azumaya, Caleigh M. , Madden, Benjamin , Krengel, Ute , Meves, Alexander , Heim, Joel B , Cordara, Gabriele , Chan, Matthew C , Johannesen, Hedda , Charlesworth, Cristine, Azumaya, Caleigh M , Madden, Benjamin , Krengel, Ute , Meves, Alexander , Campbell, Melody G , Heim, Joel B. , Li, Ming , Campbell, Melody G.

Mayo Clinic

No container title available | January 10, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.01.08.631572 | PMID 39829743 Get It

Summary Integrins are heterodimeric receptors important for cell adhesion and signaling. Integrin α5β1 is a key mediator of angiogenesis and its dysregulation is associated with tumor progression and metastasis. Despite numerous efforts, α5β1-targeting therapeutics have been unsuccessful due to poor efficacy and off-target effects. A contributing factor is our limited understanding of how integrin conformation influences interactions with therapeutics. Using cell-based functional assays, patient-derived xenografts, biophysics, and electron microscopy, we shed light on these relationships by characterizing two anti-α5β1 antibodies, BIIG2 and MINT1526A. We show that both antibodies bind α5β1 with nanomolar affinity, reduce tube formation in vitro , and bind overlapping epitopes that block fibronectin binding. However, using electron microscopy, we reveal that while BIIG2 binding does not substantially alter the conformational states, MINT1526A preferentially recognizes the bent conformation and restricts the conformational ensemble. These insights can guide which aspects to prioritize to improve the design of future integrin-targeted therapeutics.
The Risk of Epilepsy in Systemic Autoimmune Diseases: A Population-based Study in Olmsted County, Minnesota (P5-14.001)
Hasan, Shemonti , Nguyen, Adam, Achenbach, Sara J., Langenfeld, Hannah, Devine, Michelle F., Crowson, Cynthia S. , Nguyen, Adam, Flanagan, Eoin P. , Dubey, Divyanshu

Mayo Clinic

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000206254 Get It

MOG and AQP4 Antibodies among Children with Multiple Sclerosis and Controls
Gaudioso, Cristina , Mar, Soe , Casper, T. Charles , Codden, Rachel , Nguyen, Adam, Aaen, Gregory , Chitnis, Tanuja , Francisco, Carla , Gorman, Mark , Greenberg, Benjamin , Hart, Janace, Lotze, Timothy , Narula, Sona , Pittock, Sean J. , Rose, John , Schreiner, Teri , Tillema, Jan‐Mendelt , Wheeler, Yolanda , Gaudioso, Cristina M , Chitnis, Tanuja , Graves, Jennifer , Pittock, S J , Waubant, Emmanuelle L. , Greenberg, Benjamin M , Nguyen, Adam, Benson, Leslie, Goyal, Manu S. , Graves, Jennifer , Krupp, Lauren , Rensel, Mary R. , Rodriguez, Moses , Schreiner, Teri , Waldman, Amy , Weinstock‐Guttman, Bianca , Flanagan, Eoin P.

Mayo Clinic

Annals of Neurology | September 11, 2022 | Volume: 93 | Issue: 2 | Pages: 271-284

10.1002/ana.26502 | PMID 36088544 Get It

Objective The purpose of this study was to determine the frequency of myelin oligodendrocyte glycoprotein (MOG)‐IgG and aquaporin‐4 (AQP4)‐IgG among patients with pediatric‐onset multiple sclerosis (POMS) and healthy controls, to determine whether seropositive cases fulfilled their respective diagnostic criteria, to compare characteristics and outcomes in children with POMS versus MOG‐IgG‐associated disease (MOGAD), and identify clinical features associated with final diagnosis. Methods Patients with POMS and healthy controls were enrolled at 14 US sites through a prospective case–control study on POMS risk factors. Serum AQP4‐IgG and MOG‐IgG were assessed using live cell‐based assays. Results AQP4‐IgG was negative among all 1,196 participants, 493 with POMS and 703 healthy controls. MOG‐IgG was positive in 30 of 493 cases (6%) and zero controls. Twenty‐five of 30 patients positive with MOG‐IgG (83%) had MOGAD, whereas 5 of 30 (17%) maintained a diagnosis of multiple sclerosis (MS) on re‐review of records. MOGAD cases were more commonly in female patients (21/25 [84%] vs 301/468 [64%]; p = 0.044), younger age (mean = 8.2 ± 4.2 vs 14.7 ± 2.6 years; p < 0.001), more commonly had initial optic nerve symptoms (16/25 [64%] vs 129/391 [33%]; p = 0.002), or acute disseminated encephalomyelitis (ADEM; 8/25 [32%] vs 9/468 [2%]; p < 0.001), and less commonly had initial spinal cord symptoms (3/20 [15%] vs 194/381 [51%]; p = 0.002), serum Epstein–Barr virus (EBV) positivity (11/25 [44%] vs 445/468 [95%]; p < 0.001), or cerebrospinal fluid oligoclonal bands (5/25 [20%] vs 243/352 [69%]; p < 0.001). Interpretation MOG‐IgG and AQP4‐IgG were not identified among healthy controls confirming their high specificity for pediatric central nervous system (CNS) demyelinating disease. Five percent of those with prior POMS diagnoses ultimately had MOGAD; and none had AQP4‐IgG positivity. Clinical features associated with a final diagnosis of MOGAD in those with suspected MS included initial ADEM phenotype, younger age at disease onset, and lack of EBV exposure. ANN NEUROL 2023;93:271–284